Nuclear NF-κB expression correlates with outcome among patients with head and neck squamous cell carcinoma treated with primary chemoradiation therapy

International Journal of Radiation Oncology Biology Physics

Volumn 86, Issue 4, 2013, Pages 785-790

  Balermpas, Panagiotis ^a   Michel, Yvonne ^a   Wagenblast, Jens ^a   Seitz, Oliver ^a   Sipek, Florian ^a   Rödel, Franz ^a   Rödel, Claus ^a   Fokas, Emmanouil ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMORADIATION THERAPIES; HEAD-AND-NECK SQUAMOUS CELL CARCINOMA; LYMPH NODE METASTASIS; METHODS AND MATERIALS; MULTI VARIATE ANALYSIS; PROGRESSION FREE SURVIVAL; SIGNIFICANT DIFFERENCES; TOTAL RADIATION DOSE;

BIOPSY; CHEMOTHERAPY; MULTIVARIANT ANALYSIS; PATHOLOGY; PATIENT MONITORING;

CHEMORADIOTHERAPY;

CARBOPLATIN; CISPLATIN; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOMYCIN; SYNAPTOTAGMIN I;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL FEATURE; CONTINUOUS INFUSION; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; LIVER TOXICITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; MUCOSA INFLAMMATION; NEUROTOXICITY; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION DOSE FRACTIONATION; SKIN TOXICITY;

ANALYSIS OF VARIANCE; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; DISEASE PROGRESSION; DOSE FRACTIONATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NF-KAPPA B; SURVIVAL RATE; TRANSCRIPTION FACTOR RELA; TREATMENT OUTCOME;

EID: 84879208087     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.04.001     Document Type: Article

References (20)

1. J.P. Pignon, J. Bourhis, and C. Domenge Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Mach-nc collaborative group. Meta-analysis of chemotherapy on head and neck cancer Lancet 355 2000 949 955
2. A. Oeckinghaus, M.S. Hayden, and S. Ghosh Crosstalk in NF-kappab signaling pathways Nat Immunol 12 2011 695 708
3. B.B. Aggarwal Nuclear factor-kappaB: The enemy within Cancer Cell 6 2004 203 208
4. J.G. Izzo, U. Malhotra, and T.T. Wu Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma J Clin Oncol 24 2006 748 754
5. T.G. Sommermann, K. O'Neill, and D.R. Plas IKKbeta and NF-kappab transcription govern lymphoma cell survival through AKT-induced plasma membrane trafficking of GLUT1 Cancer Res 71 2011 7291 7300
6. T. Mukhopadhyay, J.A. Roth, and S.A. Maxwell Altered expression of the p50 subunit of the nf-kappa b transcription factor complex in non-small cell lung carcinoma Oncogene 11 1995 999 1003
7. M.M. Abdel-Latif, J. O'Riordan, and H.J. Windle NF-kappaB activation in esophageal adenocarcinoma: Relationship to barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy Ann Surg 239 2004 491 500
8. F.G. Ondrey, G. Dong, and J. Sunwoo Constitutive activation of transcription factors NF-(kappa)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines Mol Carcinog 26 1999 119 129
9. D.C. Duffey, Z. Chen, and G. Dong Expression of a dominant-negative mutant inhibitor-kappabalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo Cancer Res 59 1999 3468 3474
10. C.H. Chung, J.S. Parker, and K. Ely Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma Cancer Res 66 2006 8210 8218
11. P. Arun, M.S. Brown, and R. Ehsanian Nuclear NF-kappaB p65 phosphorylation at serine 276 by protein kinase a contributes to the malignant phenotype of head and neck cancer Clin Cancer Res 15 2009 5974 5984
12. P.L. Zhang, P.K. Pellitteri, and A. Law Overexpression of phosphorylated nuclear factor-kappa B in tonsillar squamous cell carcinoma and high-grade dysplasia is associated with poor prognosis Mod Pathol 18 2005 924 932
13. M. Yan, Q. Xu, and P. Zhang Correlation of NF-kappaB signal pathway with tumor metastasis of human head and neck squamous cell carcinoma BMC Cancer 10 2010 437
14. P. O-Charoenrat, P.H. Rhys-Evans, and S.A. Eccles Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck Arch Otolaryngol Head Neck Surg 127 2001 813 820
15. S. Mehrotra, L.R. Languino, and C.M. Raskett IAP regulation of metastasis Cancer Cell 17 2010 53 64
16. A. Quintana, F.X. Avilés, and X. Terra Overexpression of the nuclear factor-kappa B (p65) in association with local failure in patients with head and neck carcinoma undergong radiotherapy or chemoradiotherapy Head Neck 35 2013 370 375
17. K. Yoshida, R. Sasaki, and H. Nishimura Nuclear factor-kappaB expression as a novel marker of radioresistance in early-stage laryngeal cancer Head Neck 32 2010 646 655
18. N. Kozakai, E. Kikuchi, and M. Hasegawa Enhancement of radiosensitivity by a unique novel NF-kappaB inhibitor, DHMEQ, in prostate cancer Br J Cancer 107 2012 652 657
19. C. Van Waes, A.A. Chang, and P.F. Lebowitz Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma Int J Radiat Oncol Biol Phys 63 2005 1400 1412
20. G.J. Kubicek, R.S. Axelrod, and M. Machtay Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies Int J Radiat Oncol Biol Phys 83 2012 1192 1197